Tysabri and PML: What Arizona Patients Need to Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Occupational Risk

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This serious brain infection is a known but rare complication. Building on decades of research into biologic therapies, this page provides a clear checklist for Arizona patients to recognize symptoms and discuss monitoring with their healthcare provider.

Understanding Tysabri and Its Risks

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that the drug increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML occurs in patients who are immunocompromised, and Tysabri's mechanism of action—blocking immune cell migration into the central nervous system—creates a state of localized immunosuppression that can allow JCV to reactivate and infect oligodendrocytes, leading to demyelination and neurological decline. Clinical presentation of PML typically includes subacute onset of focal neurological deficits such as weakness, gait disturbance, visual field cuts, cognitive impairment, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. The FDA Adverse Event Reporting System (FAERS) data for Tysabri lists fatigue, multiple sclerosis relapse, headache, gait disturbance, and balance disorder among the most frequently reported adverse events, reflecting the overlap between PML symptoms and underlying disease progression (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). However, PML is a distinct and far more severe complication, with mortality rates of 30-50% and survivors often left with permanent disability.

Risk Factors and Monitoring for PML

Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that these factors should be considered in the context of expected benefit when initiating and continuing treatment. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, the adequacy of risk communication has been questioned, particularly regarding whether patients fully understand the magnitude of PML risk and the need for vigilant monitoring. For patients in Arizona who have developed PML after Tysabri exposure, legal considerations involve the statute of limitations for filing a product liability or medical malpractice claim. Arizona's statute of limitations for personal injury actions is generally two years from the date the injury is discovered or reasonably should have been discovered. Given that PML symptoms can mimic multiple sclerosis relapses, the date of discovery may be delayed until a definitive diagnosis is made via MRI and CSF analysis.

Legal Considerations for Arizona Patients

The timeline between Tysabri exposure and documented harm is critical: PML typically occurs after prolonged treatment, often beyond two years, but cases have been reported after shorter durations. The latency period complicates the determination of when the statute begins to run, as patients may not immediately attribute neurological decline to PML rather than their underlying disease. Attorney considerations for affected patients include evaluating whether the manufacturer provided adequate warnings about PML risk. The boxed warning and TOUCH Prescribing Program are designed to inform patients and prescribers, but questions may arise about whether these measures were sufficient in individual cases. Patients must also demonstrate that Tysabri caused their PML, which requires medical evidence linking the drug to the infection. The mechanistic pathway is well-established: Tysabri inhibits alpha-4 integrin, preventing lymphocyte trafficking into the brain, thereby reducing immune surveillance against JCV. This allows the virus to replicate unchecked, leading to PML. Expert testimony from neurologists and infectious disease specialists is often necessary to establish causation. In summary, Tysabri-associated PML is a devastating complication with high morbidity and mortality. Patients in Arizona who have been harmed should be aware of the two-year statute of limitations from the date of discovery, which may be later than the initial onset of symptoms. Legal counsel experienced in pharmaceutical litigation can help navigate the complexities of proving causation and assessing the adequacy of warnings. The risk factors identified in the prescribing information—anti-JCV antibody status, treatment duration, and prior immunosuppressant use—are central to both clinical management and legal evaluation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Arizona?

Arizona's statute of limitations for personal injury actions is generally two years from the date the injury is discovered or reasonably should have been discovered. For PML, the date of discovery may be delayed until a definitive diagnosis is made via MRI and CSF analysis, as symptoms can mimic multiple sclerosis relapses.

What are the risk factors for developing PML from Tysabri?

Three established risk factors are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.